Press-release for stocks in the transportation and warehousing sector related to biotech-beach

Prices are updated after-hours

Skye Bioscience Responds to OTC Markets Promotional Policy
Published: 2023-12-11 (Crawled : 16:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 396.0% | O: 10.0% H: 15.58% C: 3.9%
bioscience

| 620.33% | O: -0.31% H: 0.0% C: -23.0%
sbi-100 glaucoma agonist positive bioscience treatment trial results

Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Published: 2023-08-21 (Crawled : 16:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 109082.39% | O: -6.29% H: 17.45% C: -9.4%
antibody phase 2

Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
Published: 2023-05-17 (Crawled : 14:20) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 119624.14% | O: 3.45% H: 3.33% C: -3.33%
six agonist bioscience trial

| 66669.23% | O: -3.85% H: 8.0% C: 1.2%
sbi-100 arm approval bioscience research study phase 1

Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-03-07 (Crawled : 15:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 57766.67% | O: -9.67% H: 10.33% C: 7.01%
sbi-100 trial bioscience ophthalmic emulsion phase 1

Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study
Published: 2023-02-23 (Crawled : 16:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 58351.18% | O: 1.01% H: 25.67% C: 7.67%
sbi-100 review positive bioscience study ophthalmic emulsion phase 1

Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
Published: 2023-02-16 (Crawled : 15:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 44990.91% | O: -0.26% H: 4.17% C: -4.95%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

| -56.59% | O: -2.57% H: 1.32% C: -1.65%
bioscience

Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
Published: 2023-01-27 (Crawled : 15:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 61900.0% | O: 3.57% H: 10.0% C: -1.72%
sbi-100 trial approval bioscience phase 2 ophthalmic emulsion

Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
Published: 2022-11-17 (Crawled : 14:20) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 77747.53% | O: 12.11% H: 3.6% C: -32.0%
sbi-100 fda drug application bioscience ophthalmic emulsion

Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Published: 2022-03-03 (Crawled : 17:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K

| 44298.98% | O: 0.0% H: 7.42% C: 0.26%
glaucoma drug trial phase 1 bioscience phase 2 phase 3

Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
SKYE | $16.16 -4.77% -5.01% 110K